BioSyent Inc.

BioSyent said Q2 revenue was just over $10 million, up 14% year over year; EBITDA was just under $2.8 million, up 35%; and NIAT was over $2 million, up 28%. Q2 EBITDA margin was 27% and NIAT margin was 20%. For the first half, revenue was just over $21 million, up 27%; EBITDA was just under $6 million, up 40%; and NIAT was just over $4.3 million, up 30%, with margins of 28% and 21%, respectively. TTM EPS through June 30 was $0.72 versus $0.60 a year earlier, and Q2 EPS was $0.18. Management did not provide explicit next-quarter or full-year numerical guidance, but said momentum carried into the third quarter and that they do not expect tariff impact on the business this year.

CEO René Goehrum emphasized that momentum across Canadian Pharma, International Pharma, and the legacy business continued into the third quarter. He framed the quarter as evidence of a successful strategy of innovation, product launches, and acquisition, while stressing that the company remains focused on profitable growth and a strong, tight capital structure. He also highlighted that BioSyent has been profitable for 60 consecutive quarters and said the company is continuing to develop new FeraMAX products for 2026.

The CEO’s financial commentary emphasized operating leverage and capital returns: cash was just under $27 million at June 30, cash from operations was $12 million in the trailing 12 months, and the company returned $4 million through share buybacks and $2.2 million through dividends. He also said BioSyent bought back 19,500 shares year to date and has repurchased almost $23 million of stock since 2018, alongside $6.2 million in dividends since the program began in 2022. Management described the business as capital-light and cash-generating, with a stated priority that the first dollar of cash generation goes toward revenue growth.

There was no formal analyst Q&A in the provided transcript. Management proactively addressed tariffs, saying there had been essentially no direct impact so far, that they do not expect any impact this year, and that any future effect would be uncertain and likely limited because BioSyent has little U.S. exposure. They also explained softer Gelclair performance, saying promotional spend was pulled back while four real-world experience trials are run at cancer centers in B.C., Ontario, Quebec, and Nova Scotia.